drugset
drugset / Trial / NCT06983743

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

NCT06983743 ↗

Phase 1 Recruiting 600 enrolled Erasca, Inc. Merck Sharp & Dohme LLC · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.

Timeline

Start
2025-06-05
Primary completion
2028-05-01
Completion
2028-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ERAS-0015 Unknown — Oral
Subject Panitumumab Monoclonal antibody — Intravenous
Subject Pembrolizumab Monoclonal antibody — Intravenous
Background Gemcitabine Small molecule — —
Background Paclitaxel Small molecule — —

Indications

metastatic neoplasm